MRI Interventions, Inc. (OTCBB: MRIC) announced today that Robert C. Korn has joined the company to head its global sales and marketing efforts. Mr. Korn brings 15 years of medical device sales management experience to MRI Interventions, including an extensive background in neurosurgical and surgical navigation products. Most recently, he served as Regional Sales Director for Medtronic Surgical Technologies, with a focus on growing sales of neurosurgical and navigation products. Prior to Medtronic, Rob was Midwest Division Sales Manager for Codman, the neuroscience division of Johnson & Johnson.
“We are seeing strong growth and increasing market demand for our ClearPoint Neuro Intervention System. Rob’s deep expertise and proven sales leadership in the neurosurgical market will be invaluable to us in directing our expanding sales capabilities as we continue to accelerate our growth,” said Kimble Jenkins, CEO of MRI Interventions.
As Vice President, Global Sales & Marketing, Mr. Korn will spearhead the on-going commercialization efforts for the company’s ClearPoint system. He will be responsible for the continued growth of the company’s highly-focused sales force, which recently added two additional experienced sales representatives, both with significant neurosurgery backgrounds.
“The ClearPoint system represents a long-awaited breakthrough in minimally invasive neurosurgery, impacting a wide range of neurosurgical procedures,” said Mr. Korn. “I am thrilled to have the opportunity to lead the on-going sales and marketing efforts for this important new product platform.”About MRI Interventions, Inc. Founded in 1998, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital’s existing MRI suite, the company’s FDA-cleared ClearPoint® system is designed to enable a range of minimally invasive procedures in the brain. MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint system. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace™ system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company’s interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.MRIinterventions.com. Forward-Looking Statements Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products; our ability to successfully expand our sales and marketing capabilities; our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, future products, including our current product candidates; availability of third party reimbursement; the sufficiency of our cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; and the impact of the commercial and credit environment on us and our customers and suppliers. More detailed information on these and additional factors that could affect MRI Interventions' actual results are described in MRI Interventions' filings with the Securities and Exchange Commission, including, without limitation, the quarterly report on Form 10-Q for the quarterly period ended June 30, 2012. Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in MRI Interventions' expectations or any change in events, conditions or circumstances on which any such statements are based.